Abstract
Adrenal incidentalomas (AI) are one of the most frequent reasons for consultation in Endocrinology, as they are present in 3–10% of the general population. Up to 20% of them may have autonomous cortisol secretion (ACS), a term that refers to AI carriers with biochemical evidence of excess cortisol, but without the “specific” clinical signs of Cushing’s syndrome. As ACS is associated with an increased risk of diabetes, obesity, high blood pressure (HBP), osteoporosis, cardiovascular events, and global mortality; its correct identification is of great importance. There are different laboratory assays to detect ACS, but all of them have some limitations. The dexamethasone suppression test is the most accepted for screening. However, there is no consensus on the cutoff point that should be used. Low levels of ACTH and DHEA-S and high urinary free cortisol are also associated with ACS, but in isolation they are of little value to establish the diagnosis. Considering its clinical implications and the lack of consensus in the diagnosis and in which is the most appropriate management of these patients, this review offers a quick reference guide of ACS, presenting an exhaustive review of the topic: its definition, epidemiology, diagnosis, clinical implications, treatment, and follow-up.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12020-019-01888-y/MediaObjects/12020_2019_1888_Fig1_HTML.png)
Similar content being viewed by others
References
J. Wagner, D.C. Aron, Incidentalomas—A ‘disease’ of modern imaging technology. Best Pract. Res. Clin. Endocrinol. Metab. 26(1), 3–8 (2012). https://doi.org/10.1016/j.beem.2011.08.006
G. Favia, F. Lumachi, S. Basso, D.F. D’Amico, Management of incidentally discovered adrenal masses and risk of malignancy. Surgery 128(6), 918–924 (2000). https://doi.org/10.1067/msy.2000.109965
L. Barzon, N. Sonino, F. Fallo, G. Palu, M. Boscaro, Prevalence and natural history of adrenal incidentalomas. Eur. J. Endocrinol. 149(4), 273–285 (2003)
M.M. Grumbach, B.M. Biller, G.D. Braunstein, K.K. Campbell, J.A. Carney, P.A. Godley et al. Management of the clinically inapparent adrenal mass (‘incidentaloma’). Ann. Intern. Med. 138(5), 424–429 (2003)
P. Anagnostis, A. Karagiannis, K. Tziomalos, A.I. Kakafika, V.G. Athyros, D.P. Mikhailidis, Adrenal incidentaloma: a diagnostic challenge. HormONES 8(3), 163–184 (2009)
M. Fassnacht, W. Arlt, I. Bancos, H. Dralle, J. Newell-Price, A.M. Sahdev et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 175(2), G1–G34 (2016). https://doi.org/10.1530/EJE-16-0467
I. Chiodini, Diagnosis and treatment of subclinical hypercortisolism. J. Clin. Endocrinol. Metab. 96(5), 1223–1236 (2011). https://doi.org/10.1210/jc.2010-2722. Epub 2011 Mar 2
G. Di Dalmazi, V. Vicennati, E. Rinaldi, A.M. Morselli-Labate, E. Giampalma, C.G. Mosconi et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur. J. Endocrinol. 166(4), 669–677 (2012). https://doi.org/10.1530/EJE-11-1039. Epub 2012 Jan 20
A.A. Gheorghisan-Galateanu, M. Carsote, A. Valea, Incidentaloma: from general practice to specific endocrine frame. J. Pak. Med Assoc. 67(6), 917–922 (2017)
F. Mantero, M. Terzolo, G. Arnaldi, G. Osella, A.M. Masini, A.F. Alì et al. A survey on adrenal incidentaloma in Italy. J. Clin. Endocrinol. Metab. 85(2), 637–644 (2000)
S. Bovio, A. Cataldi, G. Reimondo, P. Sperone, S. Novello, A. Berruti et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J. Endocrinol. Invest. 29(4), 298–302 (2006)
R.T. Kloos, M. Korobkin, N.W. Thompson, I.R. Francis, B. Shapiro, M.D. Gross, Incidentally discovered adrenal masses. Cancer Treat. Res. 89, 263–292 (1997)
S.K. Mayer, L.L. Oligny, C. Deal, S. Yazbeck, N. Gagné, H. Blanchard, Childhood adrenocortical tumors: case series and reevaluation of prognosis--a 24-year experience. J. Pediatr. Surg. 32(6), 911–915 (1997)
M. Terzolo, A. Stigliano, I. Chiodini, P. Loli, L. Furlani, G.,M. Arnaldi et al. AME position statement on adrenal incidentaloma. Eur. J. Endocrinol. 164(6), 851–870 (2011). https://doi.org/10.1530/EJE-10-1147. Epub 2011 Apr 6
L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93(5), 1526–1540 (2008). https://doi.org/10.1210/jc.2008-0125. Epub 2008 Mar 11
B. Bülow, S. Jansson, C. Juhlin, L. Steen, M. Thorén, H. Wahrenberg et al. Adrenal incidentaloma—follow-up results from a Swedish prospective study. Eur. J. Endocrinol. 154(3), 419–423 (2006)
R. Libè, C. Dall’Asta, L. Barbetta, A. Baccarelli, P.R. Beck-Peccoz et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur. J. Endocrinol. 147(4), 489–494 (2002)
M. Terzolo, A. Pia, G.M. Reimondo, Subclinical Cushing’s syndrome: definition and management. Clin. Endocrinol. 76(1), 12–18 (2012). https://doi.org/10.1111/j.1365-2265.2011.04253.x
I. Chiodini, C.E. Vainicher, V. Morelli, S. Palmieri, E. Cairoli, A.S. Salcuni et al. Endogenous subclinical hypercortisolism and bone: a clinical review. Eur. J. Endocrinol. 175(6), R265–R282 (2016)
M. Boronat, A. Moreno, S. Ramón y Cajal, E. Pineda, T. Lucas, J. Estrada, Subclinical Cushing’s syndrome due to adrenal myelolipoma. Arch. Pathol. Lab Med. 121(7), 735–737 (1997)
K. Duan, K.G. Hernandez, O. Mete, Clinicopathological correlates of adrenal cushing’s syndrome. Postgrad. Med J. 91(1076), 331–342 (2015). https://doi.org/10.1136/postgradmedj-2014-202612rep
G.M. Goddard, A. Ravikumar, A.C. Levine, Adrenal mild hypercortisolism. Endocrinol. Metab. Clin. North Am. 44(2), 371–379 (2015). https://doi.org/10.1016/j.ecl.2015.02.009
N.S. Ross, Epidemiology of Cushing’s syndrome and subclinical disease. Endocrinol. Metab. Clin. North Am. 23(3), 539–546 (1994)
M. Reincke, J. Nieke, G.P. Krestin, W. Saeger, B. Allolio, W. Winkelmann, Preclinical Cushing's syndrome in adrenal incidentalomas—comparison with adrenal Cushing's syndrome. J. Clin. Endocrinol. Metab. 75(3), 826–832 (1992)
M.A. Zeiger, G.B. Thompson, Q.Y. Duh, A.H. Hamrahian, P. Angelos, D. Elaraj et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations. Endocr. Pract. 15(5), 450–453 (2009)
W.F. Young Jr., Clinical practice. The incidentally discovered adrenal mass. N. Engl. J. Med. 356(6), 601–610 (2007)
T.J. Cawood, P.J. Hunt, D. O’Shea, D. Cole, S.T. Soule, Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur. J. Endocrinol. 161(4), 513–527 (2009). https://doi.org/10.1530/EJE-09-0234. Epub 2009 May 13
A. Tabarin, S. Bardet, J. Bertherat, B. Dupas, O. Chabre, E. Hamoir et al. Exploration and management of adrenal incidentalomas. French Society of Endocrinology Consensus. Ann. Endocrinol. 69(6), 487–500 (2008). https://doi.org/10.1016/j.ando.2008.09.003. Epub 2008 Nov 20
M. Debono, M. Bradburn, M. Bull, B. Harrison, R.J. Ross, J. Newell-Price, Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J. Clin. Endocrinol. Metab. 99(12), 4462–4470 (2014). https://doi.org/10.1210/jc.2014-3007
G. Di Dalmazi, V. Vicennati, S. Garelli, E. Casadio, E. Rinaldi, E. Giampalma et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2(5), 396–405 (2014). https://doi.org/10.1016/S2213-8587(13)70211-0. Epub 2014 Jan 29
T. Katabami, R. Obi, N. Shirai, S. Naito, N. Saito, Discrepancies in results of low-and high-dose dexamethasone suppression tests for diagnosing preclinical Cushing’s syndrome. Endocr. J. 52(4), 463–469 (2005)
S. Tsagarakis, P. Kokkoris, C. Roboti, C. Malagari, J. Kaskarelis, V. Vlassopoulou et al. The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing’s syndrome. Clin. Endocrinol. 48(5), 627–633 (1998)
L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart et al. The Diagnosis of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93(5), 1526–1540 (2008). https://doi.org/10.1210/jc.2008-0125. Epub 2008 Mar 11
A.W. Meikle, Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone. Clin. Endocrinol. 16(4), 401–408 (1982)
C. Hempen, S. Elfering, A.H. Mulder, F.A. van den Bergh, R.G. Maatman, Dexamethasone suppression test: Development of a method for simultaneous determination of cortisol and dexamethasone in human plasma by liquid chromatography/tandem mass spectrometry. Ann. Clin. Biochem. 49(Pt 2), 170–176 (2012). https://doi.org/10.1258/acb.2011.011004. Epub 2012 Jan 12
G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88(12), 5593–5602 (2003)
J. Newell-Price, Diagnosis/differential diagnosis of Cushing’s syndrome: a review of best practice. Best. Pract. Res Clin. Endocrinol. Metab. 23, S5–S14 (2009)
S. Santos, E. Santos, S. Gaztambide, J. Salvador, Diagnóstico y diagnóstico diferencial del síndrome de Cushing. Endocrinol. Nutr. 56(2), 71–84 (2009). https://doi.org/10.1016/S1575-0922(09)70555-8. Epub 2009 May 1
F. Ceccato, G. Antonelli, M. Barbot, M. Zilio, L. Mazzai, R. Gatti et al. The diagnostic performance of urinary free cortisol is better than the cortisol: cortisone ratio in detecting de novo Cushing’s syndrome: the use of a LC–MS/MS method in routine clinical practice. Eur. J. Endocrinol. 171(1), 1–7 (2014). https://doi.org/10.1530/EJE-14-0061. Epub 2014 Apr 17
F. Ceccato, M. Boscaro, Cushing’s syndrome: screening and diagnosis. High Blood Press Cardiovasc Prev. 23(3), 209–215 (2016). https://doi.org/10.1007/s40292-016-0153-4
A. Kotłowska, T. Puzyn, K. Sworczak, P. Stepnowski, P. Szefer, Metabolomic biomarkers in urine of cushing’s syndrome patients. Int J. Mol. Sci. 18(2), pii: E294 (2017). https://doi.org/10.3390/ijms18020294
J. Newell-Price, X. Bertagna, A.B. Grossman, L.K. Nieman, Cushing’s syndrome. Lancet 367(9522), 1605–1617 (2006)
F. Pecori Giraldi, A. Saccani, F. Cavagnini, Assessment of ACTH assay variability: a multicenter study. Eur. J. Endocrinol. 164(4), 505–512 (2011). https://doi.org/10.1530/EJE-10-0962. Epub 2011 Jan 20
M. Terzolo, S. Bovio, A. Pia, P.A. Conton, G. Reimondo, C.T. Dall’Asta et al. Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur. J. Endocrinol. 153(2), 307–315 (2005)
D.A. Papanicolaou, N. Mullen, I. Kyrou, L.K. Nieman, Nighttime salivary cortisol: A useful test for the diagnosis of Cushing’s syndrome. J. Clin. Endocrinol. Metab. 87(10), 4515–4521 (2002)
M. Doi, N. Sekizawa, Y. Tani, K. Tsuchiya, R. Kouyama, T. Tateno et al. Late-night salivary cortisol as a screening test for the diagnosis of Cushing’s syndrome in Japan. Endocr. J. 55(1), 121–126 (2008). Epub 2008 Jan 17
B. Masserini, V. Morelli, S. Bergamaschi, F. Ermetici, C. Eller-Vainicher, A.M. Barbieri et al. The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. Eur. J. Endocrinol. 160(1), 87–92 (2009). https://doi.org/10.1530/EJE-08-0485. Epub 2008 Oct 3
F. Ceccato, M. Barbot, N. Albiger, G. Antonelli, M. Zilio, M. Todeschini et al. Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma. Endocrine 59(3), 510–519 (2018). https://doi.org/10.1007/s12020-017-1421-3. Epub 2017 Sep 27
I. Perogamvros, B.G. Keevil, D.W. Ray, P.J. Trainer, Salivary cortisone is a potential biomarker for serum free cortisol. J. Clin. Endocrinol. Metab. 95(11), 4951–4958 (2010). https://doi.org/10.1210/jc.2010-1215. Epub2010 Aug 4
M. Castro, P.C. Elias, A.R. Quidute, F.P. Halah, A.C. Moreira, Out-patient screening for Cushing’s syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J. Clin. Endocrinol. Metab. 84(3), 878–882 (1999)
K. Mészáros, G. Karvaly, Z. Márta, B. Magda, J. Tőke, N. Szücs et al. Diagnostic performance of a newly developed salivary cortisol and cortisone measurement using an LC–MS/MS method with simple and rapid sample preparation. J. Endocrinol. Invest 41(3), 315–323 (2018). https://doi.org/10.1007/s40618-017-0743-6. Epub 2017 Aug 16
S.K. Baid, N. Sinaii, M. Wade, D. Rubino, L.K. Nieman, Radioimmunoassay and tandem mass spectrometry measurement of bedtime salivary cortisol levels: a comparison of assays to establish hypercortisolism. J. Clin. Endocrinol. Metab. 92(8), 3102–3107 (2007). Epub 2007 Jun 5
E. Badrick, C. Kirschbaum, M. Kumari, The relationship between smoking status and cortisol secretion. J. Clin. Endocrinol. Metab. 92(3), 819–824 (2007). Epub 2006 Dec 19
A. Tanabe, M. Naruse, T. Nishikawa, T. Yoshimoto, T. Shimizu, T. Seki et al. Autonomy of cortisol secretion in clinically silent adrenal incidentaloma. Horm. Metab. Res. 33(7), 444–450 (2001)
Z. Bencsik, I. Szabolcs, Z. Kovács, A. Ferencz, A. Vörös, I. Kaszás et al. Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected adrenal tumors. J. Clin. Endocrinol. Metab. 81(5), 1726–1729 (1996)
J.M. Lee, M.K. Kim, S.H. Ko, J.M. Koh, B.Y. Kim, S.W. Kim et al. Clinical Guidelines for the management of adrenal incidentaloma. Endocrinol. Metab. 32(2), 200–218 (2017). https://doi.org/10.3803/EnM.2017.32.2.200
S. Yener, H. Yilmaz, T. Demir, M. Secil, A. Comlekci, DHEAS for the prediction of subclinical Cushing’s syndrome: perplexing or advantageous? Endocrine 48(2), 669–676 (2015). https://doi.org/10.1007/s12020-014-0387-7. Epub 2014 Aug 22
G. Di Dalmazi, F. Fanelli, M. Mezzullo, E. Casadio, E. Rinaldi, S. Garelli et al. Steroid profiling by LC-MS/MS in nonsecreting and subclinical cortisol-secreting adrenocortical adenomas. J. Clin. Endocrinol. Metab. 100(9), 3529–3538 (2015). https://doi.org/10.1210/JC.2015-1992. Epub2015 Jul 10
A.S. Salcuni, V. Morelli, C. Eller Vainicher, S. Palmieri, E. Cairoli, A. Spada et al. Adrenalectomy reduces the risk of vertebral fractures in patients with monolateral adrenal incidentalomas and subclinical hypercortisolism. Eur. J. Endocrinol. 174(3), 261–269 (2016). https://doi.org/10.1530/EJE-15-0977. Epub 2015 Dec 2
M. Terzolo, A. Pia, A. Alì, G. Osella, G. Reimondo, S. Bovio et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J. Clin. Endocrinol. Metab. 87(3), 998–1003 (2002)
B. Masserini, V. Morelli, S. Palmieri, C. Eller-Vainicher, V. Zhukouskaya, E. Cairoli et al. Lipid abnormalities in patients with adrenal incidentalomas: Role of subclinical hypercortisolism and impaired glucose metabolism. J. Endocrinol. Invest. 38(6), 623–628 (2015). https://doi.org/10.1007/s40618-014-0232-0. Epub 2015 Jan 23
C. Scaroni, M. Zilio, M. Foti, M. Boscaro, Glucose metabolism abnormalities in cushing syndrome: from molecular basis to clinical management. Endocr. Rev. 38(3), 189–219 (2017). https://doi.org/10.1210/er.2016-1105
E. Ellis, P.K. Chin, P.J. Hunt, H. Lunt, J.G. Lewis, S.G. Soule, Is late-night salivary cortisol a better screening test for possible cortisol excess than standard screening tests in obese patients with Type 2. Diabetes? N. Z. Med J. 125(1353), 47–58 (2012)
K. Mullan, N. Black, A. Thiraviaraj, P.M. Bell, C. Burgess, S.J. Hunter et al. Is there value in routine screening for Cushing’s syndrome in patients with diabetes? J. Clin. Endocrinol. Metab. 95(5), 2262–2265 (2010). https://doi.org/10.1210/jc.2009-2453. Epub 2010 Mar 17
L. Gagliardi, I.M. Chapman, P. O’Loughlin, D.J. Torpy, Screening for subclinical Cushing’s syndrome in type 2 diabetes mellitus: low false-positive rates with nocturnal salivary cortisol. Horm. Metab. Res. 42(4), 280–284 (2010). https://doi.org/10.1055/s-0029-1246191. Epub 2010 Jan 29
G.B. Cansu, S. Atılgan, M.K. Balcı, R. Sarı, S. Özdem, H.A. Altunbaş, Which type 2 diabetes mellitus patients should be screened for subclinical Cushing’s syndrome? Hormone. 16(1), 22–32 (2017). https://doi.org/10.14310/horm.2002.1716
A.M. Isidori, C. Graziadio, R.M. Paragliola, A. Cozzolino, A.G. Ambrogio, A. Colao et al. The hypertension of Cushing’s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J. Hypertens. 33(1), 44–60 (2015). https://doi.org/10.1097/HJH.0000000000000415
T. Mancini, B. Kola, F. Mantero, M. Boscaro, G. Arnaldi, High cardiovascular risk in patients with Cushing’s syndrome according to 1999WHO/ISH guidelines. Clin. Endocrinol. 61(6), 768–777 (2004)
Bancos I., Alahdab F., Crowley R.K., Chortis V., Delivanis D.A., Erickson D6 et al. Therapy of endocrine disease: improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing’s syndrome: a systematic review and meta-analysis. Eur. J. Endocrinol. 2016;175(6):R283–R295. Epub 2016 Jul 22.
M. Grasso, M. Boscaro, C. Scaroni, F. Ceccato, Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor. High. Blood Press Cardiovasc Prev. 25(4), 345–354 (2018). https://doi.org/10.1007/s40292-018-0288-6. Epub 2018 Nov 10
I. Chiodini, M. Torlontano, V. Carnevale, G. Guglielmi, M. Cammisa, V. Trischitta et al. Bone loss rate in adrenal incidentalomas: a longitudinal study. J. Clin. Endocrinol. Metab. 86(11), 5337–5341 (2001)
V. Morelli, C. Eller-Vainicher, A.S. Salcuni, F. Coletti, L. Iorio, G. Muscogiuri et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study. J. Bone Miner. Res. 26(8), 1816–1821 (2011). https://doi.org/10.1002/jbmr.398
I. Chiodini, V. Morelli, B. Masserini, A.S. Salcuni, C. Eller-Vainicher, R. Viti et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J. Clin. Endocrinol. Metab. 94(9), 3207–3214 (2009). https://doi.org/10.1210/jc.2009-0468. Epub 2009 Jun 23
C. Eller-Vainicher, V. Morelli, F.M. Ulivieri, S. Palmieri, V.V. Zhukouskaya, E. Cairoli et al. Bone quality, as measured by trabecular bone score in patients with adrenal incidentalomas with and without subclinical hypercortisolism. J. Bone Miner. Res. 27(10), 2223–2230 (2012). https://doi.org/10.1002/jbmr.1648
R.S. Hardy, H. Zhou, M.J. Seibel, M.S. Cooper, Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy. Endocr. Rev. 39(5), 519–548 (2018). https://doi.org/10.1210/er.2018-00097
V. Morelli, F. Donadio, C. Eller-Vainicher, V. Cirello, L. Olgiati, C. Savoca et al. Role of glucocorticoid receptor polymorphism in adrenal incidentalomas. Eur. J. Clin. Invest 40(9), 803–811 (2010). https://doi.org/10.1111/j.1365-2362.2010.02330.x. Epub 2010 Jun 23
V.V. Zhukouskaya, C. Eller-Vainicher, A. Gaudio, E. Cairoli, F.M. Ulivieri, S.,V. Palmieri et al. In postmenopausal female subjects with type 2 diabetes mellitus vertebral fractures are independently associated with cortisol secretion and sensitivity. J. Clin. Endocrinol. Metab. 100(4), 1417–1425 (2015). https://doi.org/10.1210/jc.2014-4177. Epub 2015 Jan 15
L. Buckley, G. Guyatt, H.A. Fink, M. Cannon, J. Grossman, K.E. Hansen et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res. 69(8), 1095–1110 (2017). https://doi.org/10.1002/acr.23279. Epub 2017 Jun 6
S. Lekamwasam, J.D. Adachi, D. Agnusdei, J. Bilezikian, S. Boonen, F. Borgström et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos. Int. 23(9), 2257–2276 (2012). https://doi.org/10.1007/s00198-012-1958-1. Epub 2012 Mar 21
G.P. Bernini, A. Moretti, C. Oriandini, M. Bardini, C. Taurino, A. Salvetti, Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. Br. J. Cancer 92(6), 1104–1109 (2005)
S. Yener, M. Baris, A. Peker, O. Demir, B. Ozgen, M. Secil, Autonomous cortisol secretion in adrenal incidentalomas and increased visceral fat accumulation during follow-up. Clin. Endocrinol. 87(5), 425–432 (2017). https://doi.org/10.1111/cen.13408. Epub2017 Aug 2
M. Debono, J. Newell-Price, Subclinical hypercortisolism in adrenal incidentaloma. Curr. Opin. Endocrinol. Diabetes Obes. 22(3), 185–192 (2015). https://doi.org/10.1097/MED.0000000000000151
R. Rossi, L. Tauchmanova, A. Luciano, M. Di Martino, C. Battista, L. Del Viscovo et al. Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J. Clin. Endocrinol. Metab. 85(4), 1440–1448 (2000)
R. Świątkowska-stodulska, A. Skibowska-bielińska, P. Wiśniewski, K. Sworczak, Activity of selected coagulation factors in overt and subclinical hypercortisolism. Endocr. J. 62(8), 687–694 (2015). https://doi.org/10.1507/endocrj.EJ14-0539. Epub 2015 May 13
M. Karakose, B. Karbek, M. Sahin, M.S. Arslan, O. Topaloglu, G. Erden et al. The association of autoimmune thyroiditis and non-functional adrenal incidentalomas with insulin resistance. Arch. Endocrinol. Metab. 59(1), 42–46 (2015). https://doi.org/10.1590/2359-3997000000008
L. Barzon, C. Scaroni, N. Sonino, F. Fallo, A. Paoletta, M. Boscaro, Risk factors and long-term follow-up of adrenal incidentalomas. J. Clin. Endocrinol. Metab. 84(2), 520–526 (1999)
V. Morelli, A. Scillitani, M. Arosio, I. Chiodini, Follow-up of patients with adrenal incidentaloma, in accordance with the European society of endocrinology guidelines: could we be safe? J. Endocrinol. Invest. 40(3), 331–333 (2017). https://doi.org/10.1007/s40618-016-0558-x. Epub 2016 Oct 15
L. Barzon, F. Fallo, N. Sonino, M. Boscaro, Development of overt Cushing’s syndrome in patients with adrenal incidentaloma. Eur. J. Endocrinol. 146(1), 61–66 (2002)
I.C. Mitchell, R.J. Auchus, K. Juneja, A.Y. Chang, S.A. Holt, W.H. Snyder et al. Subclinical Cushing’s syndrome is not subclinical: improvement after adrenalectomy in 9 patients. Surgery 142(6), 900–905 (2007)
A. Toniato, I. Merante-Boschin, G. Opocher, M.R. Pelizzo, F. Schiavi, E. Ballotta, Surgical versus conservative management for subclinical cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann. Surg. 249(3), 388–391 (2009). https://doi.org/10.1097/SLA.0b013e31819a47d2
S. Midorikawa, H. Sanada, S. Hashimoto, T. Suzuki, T. Watanabe, The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin. Endocrinol. 54(6), 797–804 (2001)
R. Emral, A.R. Uysal, M. Asik, S. Gullu, D. Corapcioglu, V. Tonyukuk et al. Prevalence of subclinical Cushing’s syndrome in 70 patients with adrenal incidentaloma: clinical, biochemical and surgical outcomes. Endocr. J. 50(4), 399–408 (2003)
M. Tsuiki, A. Tanabe, S. Takagi, M. Naruse, K. Takano, Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing’s syndrome. Endocr. J. 55(4), 737–745 (2008). Epub 2008 May 28
J. Patrova, I. Jarocka, H. Wahrenberg, H. Falhammar, Clinical outcomes in adrenal incidentaloma: experience from one center. Endocr. Pract. 21(8), 870–877 (2015). https://doi.org/10.4158/EP15618.OR. Epub 2015 Jun 29
I. Bourdeau, N. El Ghorayeb, N. Gagnon, A. Lacroix, Management of endocrine disease: Differential diagnosis, investigation and therapy of bilateral adrenal incidentalomas. Eur. J. Endocrinol. 179(2), R57–R67 (2018). https://doi.org/10.1530/EJE-18-0296. Epub 2018 May 10
N. El Ghorayeb, I. Bourdeau, A. Lacroix, Multiple aberrant hormone receptors in Cushing’s syndrome. Eur. J. Endocrinol. 173(4), M45–M60 (2015). https://doi.org/10.1530/EJE-15-0200. Epub 2015 May 13
R. Libé, J. Coste, L. Guignat, F. Tissier, H. Lefebvre, G. Barrande et al. Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing’s syndrome. Eur. J. Endocrinol. 163(1), 129–138 (2010). https://doi.org/10.1530/EJE-10-0195. Epub 2010 Apr 8
D.A. Vassiliadi, G. Ntali, T. Stratigou, M. Adali, S. Tsagarakis, Aberrant cortisol responses to physiological stimuli in patients presenting with bilateral adrenal incidentalomas. Endocrine 40(3), 437–444 (2011). https://doi.org/10.1007/s12020-011-9490-1. Epub 2011 May 20
E. Vassilatou, A. Vryonidou, D. Ioannidis, S.A. Paschou, M. Panagou, I. Tzavara, Bilateral adrenal incidentalomas differ from unilateral adrenal incidentalomas in subclinical cortisol hypersecretion but not in potential clinical implications. Eur. J. Endocrinol. 171(1), 37–45 (2014). https://doi.org/10.1530/EJE-13-0848. Epub 2014 Apr 17
J.D. Pasternak, C.D. Seib, N. Seiser, J.B. Tyrell, C. Liu, R.M. Cisco et al. Differences between bilateral adrenal incidentalomas and unilateral lesions. JAMA Surg. 150(10), 974–978 (2015). https://doi.org/10.1001/jamasurg.2015.1683
E. Debillon, F.L. Velayoudom-Cephise, S. Salenave, P. Caron, P. Chaffanjon, T. Wagner et al. Unilateral adrenalectomy as a first-line treatment of cushing’s syndrome in patients with primary bilateral macronodular adrenal hyperplasia. J. Clin. Endocrinol. Metab. 100(12), 4417–4424 (2015). https://doi.org/10.1210/jc.2015-2662. Epub 2015 Oct 9
Y. Xu, W. Rui, Y. Qi, C. Zhang, J. Zhao, X. Wang et al. The role of unilateral adrenalectomy in corticotropin-independent bilateral adrenocortical hyperplasias. World J. Surg. 37(7), 1626–1632 (2013). https://doi.org/10.1007/s00268-013-2059-9
V. Morelli, G. Reimondo, R. Giordano, S. Della Casa, C. Policola, S. Palmieri et al. Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J. Clin. Endocrinol. Metab. 99(3), 827–834 (2014). https://doi.org/10.1210/jc.2013-3527. Epub 2014 Jan 1
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Araujo-Castro, M., Sampedro Núñez, M.A. & Marazuela, M. Autonomous cortisol secretion in adrenal incidentalomas. Endocrine 64, 1–13 (2019). https://doi.org/10.1007/s12020-019-01888-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-019-01888-y